logo
logo

Obsidian Therapeutics Announces Closing Of $115 Million Series B Financing

Sep 09, 2021•almost 4 years ago

Amount Raised

$115 Million

Round Type

series b

Cambridge

Description

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover Fund (TCGX). Additional new investors participating in the financing include RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital. Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing. Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.

Company Information

Company

Obsidian Therapeutics

Location

Cambridge, Maryland, United States

About

Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE® technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech